Treatment of Growing Teratoma Syndrome
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
gests, approaches to the same challenges around the world.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the phase 1 experience, a partial response was achieved in a patient with growing teratoma syndrome (73), with clinical benefit later confirmed in a larger group of patients with teratoma (74): stable disease was noted in 19 of 74 patients with advanced solid tumors, with nine patients receiving ten or more cycles on either the 3/1 or 2/1 schedule.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Schwartz, G. K., & Shah, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5594 · Cited by 817
Logothetis, C. J., Samuels, M. L., Trindade, A., & Johnson, D. E. (1982) · Cancer · doi:10.1002/1097-0142(19821015)50:8<1629::aid-cncr2820500828>3.0.co;2-1 · Cited by 552
Surgical Management of Growing Teratoma Syndrome: The M. D. Anderson Cancer Center Experience
Spiess, P. E., Kassouf, W., Brown, G. A., Kamat, A. M., Liu, P., Gómez, J. A., Tu, S., Tannir, N. M., & Pisters, L. L. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.11.086 · Cited by 106
Deregulation of the RB pathway in human testicular germ cell tumours
Bartkova, J., Lukas, C., Sørensen, C. S., Meyts, E. R., Skakkebæk, N. E., Lukas, J., & Bartek, J. (2003) · The Journal of Pathology · doi:10.1002/path.1353 · Cited by 56
Anger, B., Oettgen, H. F., Old, L. J., Bockman, R. S., Andreeff, M., Erlandson, R. A., Saigo, P. E., Jhanwar, S. C., Kameya, T., Wright, W., et al. (1982) · Cancer · doi:10.1002/1097-0142(19821015)50:8<1462::aid-cncr2820500804>3.0.co;2-1 · Cited by 38
O'Dwyer, P. J., Eckhardt, S., Haller, D. G., Tepper, J. E., Ahnen, D. J., Hamilton, S. R., Benson, A. B., Rothenberg, M. L., Petrelli, N. J., Lenz, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6900 · Cited by 31
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366
Self-citationMichaud, K., Solomon, D. A., Oermann, E., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 319
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
Self-citationSchwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Self-citationMultiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
Molecular pathways: CDK4 inhibitors for cancer therapy
Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer
Koster, R., di Pietro, A., Timmer-Bosscha, H., Gibcus, J. H., van den Berg, A., Suurmeijer, A. J., Bischoff, R., Gietema, J. A., & de Jong, S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41939 · Cited by 226
Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226
Targeting the RB-pathway in Cancer Therapy
Knudsen, E. S., & Wang, J. Y. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0787 · Cited by 203
Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41402 · Cited by 168
Clark, A. S., Karasic, T. B., DeMichele, A. M., Vaughn, D. J., O’Hara, M. H., Perini, R. F., Zhang, P. J., Lal, P., Feldman, M. D., Gallagher, M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4701 · Cited by 143
Targeted therapy for melanoma: rational combinatorial approaches
Kwong, L. N., & Davies, M. A. (2013) · Oncogene · doi:10.1038/onc.2013.34 · Cited by 133
Targeting cell cycle and hormone receptor pathways in cancer
Comstock, C. E. S., Augello, M. A., Goodwin, J. F., de Leeuw, R., Schiewer, M. J., Ostrander, W. F., Burkhart, R. A., McClendon, A. K., McCue, P. A., Trabulsi, E. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.83 · Cited by 113
Vaughn, D. J., Hwang, W., Lal, P., Rosen, M. A., Gallagher, M., & O'Dwyer, P. J. (2015) · Cancer · doi:10.1002/cncr.29213 · Cited by 74
Self-citationMiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma
Cai, K., Wang, Y., & Bao, X. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-73 · Cited by 73
Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer
Koster, R., van Vugt, M. A. T. M., Timmer‐Bosscha, H., Gietema, J. A., & de Jong, S. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.13 · Cited by 66
MLL fusion-driven activation ofCDK6potentiates proliferation inMLL-rearranged infant ALL
der Linden, M. V., Willekes, M., Roon, E. H. J. V., Seslija, L., Schneider, P., Pieters, R., & Stam, R. W. (2014) · Cell Cycle · doi:10.4161/cc.27757 · Cited by 59
Platinum-refractory germ cell tumors: an update on current treatment options and developments
Oing, C., Alsdorf, W. H., Amsberg, G. V., Oechsle, K., & Bokemeyer, C. (2016) · World Journal of Urology · doi:10.1007/s00345-016-1898-z · Cited by 48
Therapeutic approaches for refractory germ cell cancer
Oing, C., Seidel, C. A., & Bokemeyer, C. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1450630 · Cited by 45
Overcoming Chemotherapy Resistance in Germ Cell Tumors
Országhová, Z., Kaľavská, K., Mego, M., & Chovanec, M. (2022) · Biomedicines · doi:10.3390/biomedicines10050972 · Cited by 51
Growing teratoma syndrome: Clinical and radiographic characteristics
Lee, D. J., Djaladat, H., Tadros, N. N., Movassaghi, M., Tejura, T. K., Duddalwar, V. A., & Daneshmand, S. (2014) · International Journal of Urology · doi:10.1111/iju.12466 · Cited by 42
Subbiah, V., Meric‐Bernstam, F., Mills, G. B., Shaw, K. R. M., Bailey, A. M., Rao, P., Ward, J. F., & Pagliaro, L. C. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0052-x · Cited by 39
Schmidtova, S., Kaľavská, K., & Kučerová, L. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0730-x · Cited by 36
Investigational targeted therapies for the treatment of testicular germ cell tumors
Oing, C., Kollmannsberger, C., Oechsle, K., & Bokemeyer, C. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1195808 · Cited by 35
Narayan, V., Hwang, W., Lal, P., Rosen, M. A., Gallagher, M., O'Dwyer, P. J., & Vaughn, D. J. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.03.010 · Cited by 35
Brighi, N., Conteduca, V., Lolli, C., Gurioli, G., Schepisi, G., Palleschi, M., Mariotti, M., Casadei, C., & Giorgi, U. D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103199 · Cited by 33
PD0332991 (Palbociclib) for treatment of pediatric intracranial growing teratoma syndrome
Schultz, K. A. P., Petronio, J. A., Bendel, A. E., Patterson, R., & Vaughn, D. J. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25338 · Cited by 30
Growing Teratoma Syndrome of the Ovary after Fertility-Sparing Surgery and Successful Pregnancy
Matsushita, H., Arai, K., Fukase, M., Takayanagi, T., & Ikarashi, H. (2010) · Gynecologic and Obstetric Investigation · doi:10.1159/000273205 · Cited by 28
Loh, K. P., & Fung, C. (2017) · Rare Tumors · doi:10.4081/rt.2017.6867 · Cited by 23
Targeted treatment approaches in refractory germ cell tumors
Gálvez, L., Sánchez‐Muñoz, A., Ribelles, N., Sáez, M. I., Baena, J., Ruíz, S., Ithurbisquy, C., & Alba, E. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.005 · Cited by 26
Kataria, S. P., Varshney, A. N., Nagar, M., Mandal, A. K., & Jha, V. (2016) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-016-0568-3 · Cited by 22
Weiswald, L., Hasan, M. R., Wong, J. C. T., Pasiliao, C. C., Rahman, M., Ren, J., Yin, Y., Gusscott, S., Vacher, S., Weng, A. P., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0666 · Cited by 24
Management of Germ Cell Tumors in Pediatric Patients
Weil, B. R., & Billmire, D. F. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.11.011 · Cited by 26
Pashankar, F., Murray, M. J., Gell, J. J., MacDonald, N., Shamash, J., Billmire, D. F., Klosterkemper, L., Olson, T. A., Hirsch, M. S., Lockley, M., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102453 · Cited by 27
Li, Y., Barbash, O., & Diehl, J. A. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00011-1 · Cited by 28
Growing Teratoma Syndrome: First Case Report in a 4-Year-Old Girl
Daher, P., Riachy, E., Khoury, A. E., Raffoul, L., Ghorra, C. S., & Rehayem, C. (2014) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2014.03.003 · Cited by 18
Al-jumaily, U. A. H., Al-Hussaini, M. A., Ajlouni, F., Abulruz, A., & Sultan, I. Y. (2012) · Journal of Medical Case Reports · doi:10.1186/1752-1947-6-13 · Cited by 16
Dunne, R. F., Sahasrabudhe, D. M., Messing, E. M., Jean‐Gilles, J., & Fung, C. (2014) · Rare Tumors · doi:10.4081/rt.2014.5268 · Cited by 15
Growing teratoma syndrome: Brief communication and algorithm for management
Byrd, K. A., Stany, M. P., Herbold, N. C., Leath, C. A., & Hamilton, C. A. (2013) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12084 · Cited by 15
Medeiros, F., & Strickland, K. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-44732-4.00026-1 · Cited by 15
Hsieh, M., Chen, H., Lee, C.-Y., Hung, G., Chang, T., Chen, S., Lai, J., Jaing, T., Cheng, C., Chen, J., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6017 · Cited by 14
Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma
Imran, H., Siddiqui, A. H., Wilson, F. L., & Pashankar, F. (2019) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001525 · Cited by 13
Sawicka-Żukowska, M., Krętowska-Grunwald, A., Reszeć, J., & Krawczuk‐Rybak, M. (2021) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2021.07.009 · Cited by 12
Interferon-α Treatment for Growing Teratoma Syndrome of the Testis
Inoue, M., Hisasue, S., Nagae, M., China, T., Saito, K., Isotani, S., Yamaguchi, R., Ide, H., Muto, S., & Horie, S. (2013) · Case Reports in Nephrology and Dialysis · doi:10.1159/000350897 · Cited by 12
Targeted therapies in germ cell tumors
Squillante, C. M., & Vaughn, D. J. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.09.008 · Cited by 11
“Among them, 1 patient had stable disease for 18 months, another had a partial response for 22 months and continued to receive treatment, and the third patient had stable disease for 24 months and continued to receive treatment [52].”
BackgroundEmerging Therapeutic Targets for Male Germ Cell Tumors
Fankhauser, C. D., Honecker, F. U., Beyer, J., & Bode, P. K. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0479-4 · Cited by 10
O’Hara, M. H., Jegede, O. A., Dickson, M. A., DeMichele, A. M., Piekarz, R., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L., Patton, D. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0036 · Cited by 9
Third-Line Chemotherapy and Novel Agents for Metastatic Germ Cell Tumors
Veenstra, C. M., & Vaughn, D. J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.03.005 · Cited by 10
Ando, S., Matsuoka, T., Kawai, K., Sugita, S., Joraku, A., Kojima, T., Suetomi, T., Miyazaki, J., Fujita, J., & Nishiyama, H. (2014) · International Journal of Urology · doi:10.1111/iju.12484 · Cited by 8
Pediatric Ovarian Growing Teratoma Syndrome
Rentea, R. M., Varghese, A., Ahmed, A. A., Kats, A., Manalang, M. A., Dowlut‐McElroy, T., & Hendrickson, R. J. (2017) · Case Reports in Surgery · doi:10.1155/2017/3074240 · Cited by 7
Rathod, P. S., Singh, A., Punyashree, R., Pallavi, V. R., Usha, A., Vijay, C. R., Shoba, K., & Rajshekar, K. (2020) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-020-01224-1 · Cited by 6
Priod, F., Lorge, F., Gregorio, M. D., Dupont, M., Nollevaux, M., Faugeras, L., Lawson, G., Eucher, P. M., & D'Hondt, L. A. (2017) · Case Reports in Oncology · doi:10.1159/000481397 · Cited by 6
Primitive Neuroectodermal Tumor of the Testis
Demir, T., Aliyev, A., Şeker, M., Ersöz, C., Çoban, G., & Türk, H. M. (2021) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2021.11.1362 · Cited by 6
Palbociclib (Ibrance): The First‐in‐Class CDK4/6 Inhibitor for Breast Cancer
Toogood, P. L., & Ide, N. D. (2015) · Wiley eBooks · doi:10.1002/9781118819951.ch9 · Cited by 6
Growing Teratoma Syndrome of Testicular Origin
Nassiri, N., Shah, A., & Daneshmand, S. (2018) · Urology · doi:10.1016/j.urology.2018.05.015 · Cited by 4
“Vaughn et al reported on the treatment of 3 patients with recurrent tumor burden despite surgical extirpation of GTS.(14) Cyclin-dependent kinase (CKD) mediated phosphorylation of retinoblastoma has been shown to be necessary for cell growth in mature”
BackgroundHuľová, S., Chovanec, M., Mardiak, J., Mego, M., & Pinďák, D. (2019) · Klinicka onkologie · doi:10.14735/amko2019129 · Cited by 3
Giorgi, U. D., Yuan, J., Moroni, M., Veronese, S. M., Bianchi, A. S., Broggini, M., Rosti, G., Strebhardt, K., & Ruffini, P. A. (2015) · The International Journal of Biological Markers · doi:10.5301/jbm.5000149 · Cited by 3
“Recently, a selective CDK4/6 inhibitor, PD0332991 (palbociclib), showed activity in the treatment of 1 case of relapsed nonseminomatous GCT and 3 cases of growing teratoma syndrome (21, 22).”
BackgroundOcamica, O. L., Ugarte, L., Cuadra, M., Picado, A. L., Maestro, L. M., & Lete, I. (2016) · Clinical and Experimental Obstetrics & Gynecology · doi:10.12891/ceog3191.2016 · Cited by 3
Medeiros, F., & Crum, C. P. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0764-9.00029-9 · Cited by 3
Systemic treatment options for growing teratoma syndrome
Açıkgöz, Y., Bal, Ö., Ergün, Y., Öksüzoğlu, B. Ç., Yıldız, B., & Doğan, M. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_568_19 · Cited by 2
Targeting Cyclin-Dependent Kinases for Cancer Therapy
Johnson, N., & Shapiro, G. I. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1770-6_11 · Cited by 2
Ghaouti, M., Roquet, L., Fazzalari, L., Sibert, L., & Sabourin, J. (2013) · Annales de Pathologie · doi:10.1016/j.annpat.2013.10.020 · Cited by 2
Localisation thoracique d’un growing teratoma syndrome : à propos d’un cas
Ngabou, U. D., Dusaud, M., Boddaert, G., Grand, B., Houlgatte, A., & Pons, F. (2014) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2013.12.007 · Cited by 2
What is new about germ cell ovarian tumors?
Pilarska, I., Grabska, K., Fudalej, M. M., Deptała, A., & Badowska-Kozakiewicz, A. M. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2022.0013 · Cited by 2
Chaudhuri, T., Babu, G., Lakshmaiah, K., Dasappa, L., Jacob, L. A., Babu, M. S., Rudresha, A. H., Lokesh, K. N., & Rajeev, L. (2019) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_87_18 · Cited by 2
“reported a Phase I trial of three patients with growing teratoma syndrome.[37] The efficacy of palbociclib has been investigated further in a Phase II study of thirty patients with relapsed, Rb1‐proficient germ‐cell tumors, in which eight patients had a PFS duration of >24 weeks.”
BackgroundRao, B., & Pagliaro, L. C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2232-1.00020-6 · Cited by 1
Challenges in the diagnosis of growing teratoma syndrome: two case reports
Sinichenkova, K. Y., Tyutikova, E. S., Likar, Y. N., Митрофанова, А. М., Konovalov, D. M., Литвинов, Д. В., & Zhukov, N. V. (2020) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2020-19-4-126-132 · Cited by 1
A case of ovarian growing teratoma syndrome successfully treated with laparoscopy
Abe, A., Utsugi, K., Nomura, H., Matoda, M., Omatsu, K., Kato, K., & Takesima, N. (2012) · JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY · doi:10.5180/jsgoe.28.521 · Cited by 1
Cyclin D1-AR Crosstalk: Potential Implications for Therapeutic Response in Prostate Cancer
Schiewer, M. J. (2012) · Defense Technical Information Center (DTIC) · doi:10.21236/ada564541
Casimiro, M. C., Pestell, R. G., & Knudsen, E. S. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_13-4
Changing the balance in apoptosis: key to enhance cisplatin sensitivity of testicular cancer
Koster, R. (2010) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Central Nervous System Nongerminomatous Germ Cell Tumors
Phi, J. H., Lyu, C. J., & Kim, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-55430-3_15
Matei, D. E., Frazier, A. L., Hurteau, J. A., & Pashankar, F. (2017) · Wiley eBooks · doi:10.1002/9781119196235.ch35 · Cited by 1
Casimiro, M. C., Pestell, R. G., & Knudsen, E. S. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_13-5
Casimiro, M. C., Pestell, R. G., & Knudsen, E. S. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_13
Сложности диагностики синдрома растущей тератомы на примере двух клинических наблюдений.
Sinichenkova, K. Y., Tyutikova, E. S., Ликарь, Ю. Н., Митрофанова, А. М., Коновалов, Д. М., Литвинов, Д. В., & Жуков, Н. В. (2020) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/j.239
Chebat, A., Saab, R., Bhosale, P., Lawson, B. C., Meyer, L., Gershenson, D. M., Sun, C., Nitecki, R., & Shafer, A. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.104815
Metadata
- Authors
- Vaughn, D. J., Flaherty, K., Lal, P., Gallagher, M., O'Dwyer, P., Wilner, K., Chen, I., & Schwartz, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-01-22
- Volume
- 360
- Issue
- 4
- Pages
- 423-424
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2038616177
- Cited by
- 82
- References
- 5
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 7 · 2016: 7 · 2015: 8 · 2014: 11 · 2013: 7 · 2012: 7
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Teratomas and Epidermoid Cysts
- Health Sciences › Medicine › Surgery › Testicular diseases and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- growing teratoma syndrome, teratoma, germ cell tumors
- MeSH terms
- Adult, Antineoplastic Agents, Humans, Male, Neoplasms, Germ Cell and Embryonal, Piperazines, Pyridines, Teratoma, Retinoblastoma Protein, Neoplasms, Second Primary, Disease Progression, Cyclin-Dependent Kinases, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.